We are live on ! Find out more
NVS icon

Novartis

1,383 hedge funds and large institutions have $16.2B invested in Novartis in 2025 Q2 according to their latest regulatory filings, with 119 funds opening new positions, 494 increasing their positions, 476 reducing their positions, and 75 closing their positions.

New
Increased
Maintained
Reduced
Closed

59% more first-time investments, than exits

New positions opened: 119 | Existing positions closed: 75

21% more funds holding in top 10

Funds holding in top 10: 1417 (+3)

5% more capital invested

Capital invested by funds: $15.4B → $16.2B (+$811M)

2% more funds holding

Funds holding: 1,3561,383 (+27)

4% more repeat investments, than reductions

Existing positions increased: 494 | Existing positions reduced: 476

0.27% less ownership

Funds ownership: 6.59%6.32% (-0.27%)

19% less call options, than puts

Call options by funds: $269M | Put options by funds: $331M

Holders
1,383
Holders Change
+27
Holders Change %
+1.99%
% of All Funds
18.21%
Holding in Top 10
17
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+21.43%
% of All Funds
0.22%
New
119
Increased
494
Reduced
476
Closed
75
Calls
$269M
Puts
$331M
Net Calls
-$61.7M
Net Calls Change
-$26.9M
Name Holding Trade Value Shares
Change
Change in
Stake
HC
601
Henshaw Capital
Massachusetts
$814K
Financial Engines Advisors
602
Financial Engines Advisors
California
$811K +$340K +3,019 +82%
PBK
603
Peoples Bank (Kansas)
Kansas
$809K +$16.9K +150 +2%
SFS
604
Sowell Financial Services
Arkansas
$809K +$23.2K +206 +3%
WPC
605
Wedmont Private Capital
Pennsylvania
$803K +$3.61K +32 +0.5%
LF
606
Lantz Financial
Illinois
$802K +$1.92K +17 +0.3%
MAM
607
Marotta Asset Management
Virginia
$801K -$72.9K -647 -9%
CSP
608
Cary Street Partners
Virginia
$796K -$19.2K -170 -3%
STA
609
Summit Trail Advisors
New York
$793K +$22.2K +197 +3%
LWCFA
610
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$793K
OIA
611
OneDigital Investment Advisors
Kansas
$793K -$29.5K -262 -4%
KFC
612
Klingenstein Fields & Co
New York
$792K
T. Rowe Price Associates
613
T. Rowe Price Associates
Maryland
$792K -$5.2M -46,108 -88%
1832 Asset Management
614
1832 Asset Management
Ontario, Canada
$787K +$18K +160 +3%
BC
615
Bridgefront Capital
Texas
$785K -$300K -2,665 -29%
NPT
616
Nixon Peabody Trust
Massachusetts
$780K -$157K -1,393 -18%
GI
617
Gradient Investments
Minnesota
$777K +$118K +1,043 +19%
NRS
618
Neville Rodie & Shaw
New York
$776K -$5.64K -50 -0.8%
SI
619
Stephens Inc
Arkansas
$764K -$7.21K -64 -1%
Allianz Asset Management
620
Allianz Asset Management
Germany
$762K -$45.1K -400 -6%
MAA
621
Mraz Amerine & Associates
California
$762K +$192K +1,706 +37%
GFG
622
Goldstone Financial Group
Illinois
$762K +$155K +1,378 +28%
HIP
623
Harrell Investment Partners
Texas
$760K +$708K +6,279 New
MHC
624
May Hill Capital
Massachusetts
$759K +$235K +2,084 +50%
AWM
625
Avior Wealth Management
Nebraska
$756K +$147K +1,305 +26%

NVS Hedge Fund Activity: Q2 2025 in Review

1,383 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q2 2025, worth a combined $16.2B — up 5.3% from $15.4B a quarter earlier.

Buyers outnumbered sellers: 119 funds opened new NVS positions and 75 closed out — a net gain of 44 holders — while 494 added to existing stakes and 476 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $56.8M. The largest seller was CIBC World Market, cutting an estimated $192M.

  • 1,383 institutional investors held Novartis (NVS) as of Q2 2025, up from 1,356 in Q1 2025.
  • Funds reported $16.2B of Novartis stock for Q2 2025, up 5.3% quarter-over-quarter.
  • 119 funds opened new Novartis positions in Q2 2025 and 75 closed out, a net change of +44 holders.
  • The largest Novartis buyer in Q2 2025 was Morgan Stanley, an estimated $56.8M added.
  • The largest Novartis seller in Q2 2025 was CIBC World Market, an estimated $192M sold.

Based on aggregated 13F filings for Q2 2025.